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Abstract  
Background: High survival rates are commonly reported following 
primary percutaneous coronary intervention (PPCI) for STEMI with 
most contemporary studies reporting overall survival.   
Aims: To describe survival following PPCI for STEMI corrected for 
non-cardiovascular deaths by reporting relative survival and 
investigate clinically significant factors associated with poor long term 
outcomes. 
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Methods and Results: Using the prospective UK PCI registry, PPCI 
cases (n=88,188; 2005-2013) were matched to mortality data for the 
UK populace. Crude 5-year relative survival was 87.1%for the 
patients undergoing PPCI and 94.7% for patients <55 years. 
Increasing age was associated with excess mortality up to 4 years 
following PPCI (56-65 years: excess mortality rate ratio (EMRR) 
1.61, 95% CI 1.46-1.79; 66-75 years: 2.49, 2.26-2.75; >75 years: 
4.69, 4.27-5.16). After 4 years, there was no excess mortality for 
ages 56-65 years (EMRR 1.27, 95% CI 0.95-1.70), but persisting 
excess mortality for older groups (66-75 years: EMRR 1.72, 95% CI 
1.30-2.27; >75 years: 1.66, 1.15–2.41). Excess mortality was 
associated with cardiogenic shock (EMRR 6.10, 95% CI 5.72-6.50), 
renal failure (2.52, 2.27-2.81), left main stem stenosis (1.67, 1.54-
1.81), diabetes (1.58, 1.47-1.69), previous MI (1.52, 1.40-1.65) and 
female sex (1.33, 1.26-1.41);  whereas stent deployment (0.46, 0.42-
0.50), radial access (0.70, 0.63-0.71) and previous PCI (0.67, 0.60-
0.75) were protective.  
Conclusions: Following PPCI for STEMI, long term cardiovascular 
survival is excellent. Failure to account for non-cardiovascular death 
may result in an underestimation of the efficacy of PPCI.  
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Condensed abstract 
After matching 88,188 cases of PPCI to the background UK death 
data, 5-year crude relative survival was 87% overall, and 94.7% 
among patients aged <55 years. After 4 years from PPCI, there was 
no excess mortality for patients aged 56-65 years, but older ages 
experienced ongoing excess mortality. Excess mortality was also 
significantly associated with renal failure and cardiogenic shock. 
Following PPCI relative survival was excellent, however, increasing 
age, renal failure and cardiogenic shock contribute to PPCI related 
mortality.  
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Introduction 
 
The development of specialist heart attack centres, evolving 
pharmacology, second and third generation stent technology and 
increasing expertise has resulted in a decline in short term mortality 
following ST-elevation myocardial infarction (STEMI) treated by 
primary percutaneous coronary intervention (PPCI)1, 2. However, in 
the longer term non-cardiovascular death following PPCI is common 
and failure to account for this may underestimate the impact of PPCI 
on survival. Reported rates of death following PPCI are incongruent, 
with randomised studies suggest three year mortality rates of 3-8% 
and observational cohorts report one year mortality rates of around 
10%3-6. Whilst variation in rates of death following PPCI may be due 
to unrepresentative cohorts, variable lengths of follow-up and 
different study designs, recently is has become apparent that the 
predominant cause of death following PCI may be non-
cardiovascular and this may influence how mortality is attributed to 
PPCI 1.  
 
Conventionally, the majority of studies of PPCI report all-cause 
mortality as the primary outcome 7. Whilst this establishes the high 
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human cost and overall survival advantage it fails to estimate the 
underlying comorbidity in patients presenting with STEMI or estimate 
the efficacy of treatment with PPCI on cardiovascular outcomes. In 
turn, this has potential repercussions for the design and study of new 
treatments as well as informing patients as to the risks and benefits 
of the intervention. To overcome the limitations of all-cause mortality 
some studies report cause-specific mortality – addressing cardiac 
death rather than death due to any cause8. However, these data may 
be difficult to obtain or adjudicate on and are subject to bias by 
misclassification, for example lack of objectivity on death certificates 
or surmised cause of death without post-mortem studies 9. An 
alternative method to estimate cause-specific outcomes is the 
technique of relative survival (RS), which compares outcomes 
between patients and an age and sex matched  comparator group of 
the overall population – this provides the advantage of being able to 
correct for non-cardiac death and enables  quantification of factors 
associated with excess deaths 10, 11. 
Using data from the United Kingdom PCI register (British 
Cardiovascular Intervention Society (BCIS) database), which 
includes all cases of PPCI in England and Wales; we aimed to 
estimate the relative survival of patients following PPCI and 
investigate factors associated with their excess mortality.   
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Methods 
 
Patients 
We included all National Health Service hospitals (n=111) in England 
and Wales which provided care for patients aged 18-100 years with 
STEMI and who received PPCI between 1st January 2005 and 30th 
June, 2013 (n=88,188), (Figure 1). Patient-level data concerning 
demographics, cardiovascular risk factors, medical history and 
clinical and treatment characteristics at the time of hospitalisation 
were extracted from BCIS, whereby participation is mandated for all 
PCI operators and all National Health Service hospitals. Details of 
the BCIS registry have been described previously12. For multiple 
admissions, we used the earliest record, the diagnosis of STEMI was 
formulated by the attending clinician in line with the third universal 
definition of myocardial infarction13. 
 
Mortality and follow up 
All-cause mortality data were extracted through linkage to the United 
Kingdom Office for National Statistics using each patient’s unique 
anonymised National Health Service number. Patients were followed 
for five years from date of PPCI, with censoring at the end of follow-
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up on 31st December, 2013 (Appendix A). Survival time was defined 
as the duration between the date of the procedure and the date of 
death or censoring.  
 
Relative survival 
Relative survival was defined as the observed survival of PPCI cases 
divided by the expected survival of the comparable United Kingdom 
populace, and expressed as a relative survival rate (RSR). Observed 
survival was estimated using the actuarial method which calculates 
the survival in time intervals from the effective number of patients at 
risk in that particular interval. The expected survival was estimated 
by the Ederer II method 11.  For expected survival, country-specific 
population mortality rates of the United Kingdom were based on life 
tables from the Office for National Statistics and matched to the 
cohort by age, sex and year of procedure. A relative survival rate of 
100% implies that cases of PPCI have survival rates equal to that of 
the matched, disease free background population. 
 
Excess mortality 
Excess mortality provides a measure of the additional hazard 
associated with a procedure or treatment and is expressed as a rate 
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ratio (EMRR). For example, an EMRR of 1.5 for men/women 
indicates that men experience 50% higher excess mortality than 
women after accounting for the matched background rates of death. 
A multivariable model was built based on the following covariates: 
previous myocardial infarction, diabetes, chronic renal impairment 
(creatinine >2.26mg/dl or 200micromol/l), pre-procedural cardiogenic 
shock, flow in the infarct related artery, use of mechanical ventilation, 
number of stents deployed, number of vessels attempted, previous 
PCI and family history of coronary artery disease.  The statistical 
model used collapsed life table data and generalised linear 
regression with a Poisson error structure.  We checked for time-
dependency and non-proportional hazards by fitting interaction terms 
between short-term follow up periods (<4 years and ≥4 years 
respectively) with age, which were significant (likelihood ratio test 
p=0.005). There was no evidence for non-proportional hazards for sex 
and calendar year by follow-up. Missing data were addressed using 
multiple imputation by chained equations to create 20 imputed datasets 
and model estimates pooled over each imputation. All tests were two-
tailed with 5% significance level and performed using Stata IC 
version 13.1 (StataCorp Texas USA).  
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Results 
 
The PPCI cohort comprised 73.9% men, mean age 63.4 (SD 13.1) 
years; 41.1% were smokers and 13.4% had diabetes. Over half 
(56.1%) of cases were completed via radial access route, 7.4% 
presented with cardiogenic shock, 9.3% received more than three 
stents, 4.5% had >50% left main stem disease and 0.9% had a 
history of renal disease (Table 1).  
 
Relative survival 
Over 216,846 person-years follow-up (median follow up 2.5 years), in 
total 12,178 (13.8%) patients died. Overall (crude) relative survival 
was 92.8% (95% CI, 92.6-93.0%) at 3 months, 92.5% (92.3-92.7%) 
at 6 months, 92.3% (92.1-92.5%) at 1 year and 87.1% (86.6-87.7%) 
at 5 years. One year relative survival declined with increasing age 
such that survival estimates for patients aged <55, 56-65, 66-75 
and >75 years were 97.3%, 95.3%, 91.8% and 83.1% respectively 
(Figure 2). The corresponding 5 year estimates were 95.4%, 92.8%, 
88.3% and 79.0%.   
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Excess mortality 
Up to 4 years following PPCI, compared with those less than 55 
years old there was excess mortality among patients aged 55-65 
years (EMRR 1.61, 95% CI 1.46-1.79), 66-75 years (2.49, 2.26-2.75) 
and >75 years (4.69, 4.27-5.16). After 4 years, there was no excess 
mortality for ages 56-65 years (EMRR 1.27, 95% CI 0.95-1.70), but 
ongoing excess mortality for ages 66-75 years (1.72, 1.30-2.27) 
and >75 years (1.66, 1.15-2.41) (Figure 3).  Excess mortality was a 
third higher amongst females than males (EMRR 1.33, 95% CI 95% 
1.26-1.41).  
 
Clinical factors significantly associated with increased excess 
mortality were diabetes (EMRR 1.58, 1.47-1.69), renal failure (2.52, 
2.27-2.81), pre-procedural ventilation (3.82, 3.56-4.12), pre-
procedural cardiogenic shock (6.10, 5.72-6.50), left main stem 
stenosis >50% (1.67, 1.54-1.81) and previous MI (1.52, 1.40-1.65). 
This contrasted with previous PCI (EMRR 0.67, 0.60-0.75), a family 
history of coronary artery disease (0.75, 0.69-0.81), the use of stents 
over balloon angioplasty (0.38, 0.34-0.41) and radial artery access 
(0.70, 0.63-0.71).  Interestingly, the use of radial vs femoral access 
was associated with lower excess mortality in the elderly who are at 
increased risk of bleeding (EMRR, <75 yrs. 0.70, 0.65-0.76 and ≥75 
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yrs. 0.64, 0.59-0.69) (Figure 3). Finally, the use of bare metal vs drug 
eluting stents was analysed, BMS was demonstrated to be superior 
to POBA (0.49, 0.45-0.55) and DES superior to POBA (0.27, 0.24-
0.29).  
 
 
Discussion 
 
This study of nearly 90,000 patients over five years of follow up 
addresses a key limitation of real world survival data for PPCI. For 
the first time in the literature, we report the long term relative survival 
for PPCI and investigate factors attributable to death from index 
STEMI and its treatment with PPCI.  
The methods employed here are relevant in the current era of high 
cardiovascular survival when the majority of deaths are remote from 
the date of intervention, not cardiovascular in origin and relate to the 
background risk of the population8. In particular, when studying the 
efficacy of an intervention amongst older age groups, lack of 
adjustment for increasing mortality amongst the general population 
can lead to underestimation of the interventions’ efficacy.  This study  
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provides evidence for very high rates of five year relative survival – 
between 2005 and 2013 survival was 90% for the cohort and 
approached 96% for patients aged <55 years. After adjustment for 
baseline clinical characteristics and death with the matched general 
population, evidence for excess mortality was associated with 
increasing age, renal failure, pre-procedural cardiogenic shock, 
mechanical ventilation, presence of left main stem disease, previous 
MI and femoral access. 
 
Overall, relative survival rates were lower early after PPCI, after 
which the hazards then decreased, this effect was most notably in 
the elderly. The survival for younger than 65 years old, 4 years after 
PPCI was the same as that of the age, sex, year and country 
matched background population. Previous studies report worse 
outcomes for the elderly at one (13.9% mortality), three (43.0%) and 
five years (53.6%) with increasing age being an independent risk 
factor14-16. In our study, we found that the five year survival rate 
among patients over 75 years was 53%, and 79% when adjusted for 
the age, sex, year and country-specific background rates of death. 
These data suggest that despite the survival advantage conferred 
with PPCI for STEMI, the elderly fail to reach rates of survival 
comparable with their matched counterparts in the general 
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population. We speculate that this may be due to a greater evidence-
to-practice gap in secondary preventative care after hospital 
discharge among the elderly compared with the young 2, 17, 18.  
 
We found that females had a third higher risk of excess mortality, 
consistent with other studies that have also shown that the femoral 
approach is associated with early mortality in this group19-21. Females 
also had an ongoing disadvantage, suggesting that although femoral 
access may be unfavourable in the short–term, other sex-specific 
factors including multimorbidity, mode of presentation and 
medications prescribed may influence longer-term outcome. 
 
Other factors associated with excess mortality were major pre-
existing medical conditions such as diabetes and renal failure as well 
as the presence of acute STEMI-related scenarios including 
cardiogenic shock and mechanical ventilation22. Cardiogenic shock 
conferred a six-fold increased risk of death relative to the general 
population which persisted up to five years from the date of the 
procedure. This is likely related to degree of acute myocardial 
necrosis which persists even after successful revascularisation and 
its long term counterpart – chronic LV dysfunction. 23. Our study 
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cohort included those who had PPCI for STEMI but did not include 
those having facilitated or rescue PCI. 
 
Previous myocardial infarction was associated with a 50% increase 
excess mortality. It is probable that this is a marker of infarction-
mediated left ventricular dysfunction and/or pre-existent multi vessel 
coronary artery disease – each known to impact upon survival24. We 
found that a family history of coronary artery disease and previous 
PCI were each associated with improved outcomes.  Whilst we 
cannot fully explain this, it may represent a healthy user bias – with 
those with a family history of cardiovascular disease and previous 
PCI being targeted for pharmacotherapeutic  intervention or having 
healthier behaviour 25.  
 
To date, there are a number of trials which have reported long-term 
mortality after PPCI26-28. Even though these studies demonstrate 
favourable outcomes, their interpretation is challenging because 
none have accounted for non-cardiovascular deaths or the greater 
background mortality rates among older patients1, 7.  So far, studies 
which have reported short- and medium-term outcomes are limited 
because they are historic27, 29, 30, from small cohorts31 or have been 
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derived from trials which may not be generalisable26. Furthermore, 
cohort studies may have underestimated the benefits of PPCI 
through not considering the impact of an ageing and increasingly co-
morbid population. We respond to this by analysing national registry 
data within a relative survival framework to provide an alternative, 
objective and up-to-date measure of the proportion of patients dying 
from PPCI for STEMI. 
 
Strengths and Limitations 
The strengths of this study include a national dataset with 
consecutive cases, the depth of detail, robust mortality tracking and 
the ability to match cases to the background national population by 
age, sex, and year of procedure. Survival analysis using relative 
survival and excess mortality are novel concepts in cardiovascular 
outcome evaluation and provide additional insight compared to the 
conventional Cox model or Kaplan Meier analysis32. However, biased 
estimates could be produced if the condition of interest is common 
and therefore mortality from the condition will also be represented in 
the background population. If the condition of interest is common this 
may affect the relative survival analysis, however, bias is negligible 
when assessing EMRR10.  Rates of STEMI are around 100-400 per 
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100,000 population, our sensitivity analyses demonstrated that the 
estimates derived from standard survival techniques were aligned 
with those from the relative survival modelling, except among the 
elderly where the relative survival estimates were attenuated 
reflecting the background population rates of death associated with 
ageing (Appendix B).  
A lack of information in the national life tables about co-morbidities 
directly related to PPCI may have introduced bias to the estimates 
because we could only match cases by age, sex, year of procedure 
and country. Whilst there were missing data we mitigated against 
potential bias using multiple imputation.  
 
Conclusion 
 
This nationwide study of survival following PPCI for STEMI 
standardised mortality to matched background population death data 
found that five year relative survival was very high. Among the 
elderly, however, there was evidence for significant persisting excess 
mortality which contrasted with younger age groups where survival 
rates approached those of the background population. Cardiogenic 
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shock, pre-procedural ventilation, renal failure and the femoral 
vascular access route were associated with the highest long-term 
excess mortality after PPCI for STEMI.  
 
Impact on daily practice  
Primary PCI for STEMI is an effective treatment and most patients 
have excellent long-term outcomes.  High risk groups have persisting 
excess mortality and require appropriate secondary prevention 
therapy and a targeted approach to reducing their risk of STEMI-
related death.  Further studies are required to elucidate the 
underlying mechanism of ongoing risk. 
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